Konruns Pharmaceutical 2026 Interim Report Net Profit 95.7226 Million Yuan

Earnings
โดย Jiemian·Read original
Summary · why it matters

Konruns Pharmaceutical released its 2026 interim report, with total operating revenue of 463 million yuan and net profit attributable to the parent company of 95.7226 million yuan. Net cash inflow from operating activities was 4.5587 million yuan, the asset-liability ratio was 15.68%, gross margin was 89.81%, ROE was 3.01%, and diluted earnings per share was 0.61 yuan. The number of shareholders was 15,300, and the top ten shareholders held 54.42% of total share capital.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews